格雷夫兹病市场：现况分析与预测（2024-2032）

格雷夫兹病市场预计将呈现约5%的成长率。这主要归功于有助于早期发现格雷夫兹病的诊断工具和技术的技术进步，以及对生物製药公司投资的增加。例如，2022年6月，生物製药公司Sling Therapeutics, Inc.发起了由TPG旗下The Rise Fund领投的3,500万美元A轮融资。这笔资金将支持一项 2b 期临床试验，评估该公司的研究药物 linsitinib 作为甲状腺眼疾 (TED) 的治疗方法。 TED 主要影响女性，由格雷夫兹病引起的甲状腺功能亢进患者受影响最大。

依治疗类型，市场分为抗甲状腺药物、β受体阻断剂、放射性碘治疗、手术（甲状腺切除）、辅助治疗及新兴治疗。其中，抗甲状腺药物类别预计将在预测期内出现显着增长，为治疗甲状腺功能亢进（格雷夫兹病的关键症状）提供非侵入性且有效的治疗选择。这些药物的作用是抑制甲状腺激素的产生，帮助荷尔蒙水平恢復正常并缓解症状。此外，为提高这些药物的功效和安全性而进行的持续研究和开发正在促进该领域的发展，进一步推动格雷夫兹病市场。

依最终使用者划分，市场分为医院、专科诊所、门诊手术中心及家庭医疗保健。其中，医院作为诊断、治疗和管理的主要护理点，是格雷夫兹病市场成长的主要动力。医院提供专业内分泌科医生、先进的诊断测试以及甲状腺手术和放射性碘治疗等治疗。它还促进患者教育和支持计划，以提高疾病意识和管理。医院基础设施和资源可实现高效的护理服务，对于全球有效的格雷夫兹病管理至关重要。

为了更瞭解格雷夫兹病的市场介绍，市场为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区） 、亚太地区（中国，根据全球其他地区（日本、印度、亚太地区其他地区）和其他地区的全球影响力进行分析。在预测期内，北美占据主要占有率。该地区先进的医疗基础设施有利于格雷夫兹病的早期诊断和有效管理，为市场扩张做出了重大贡献。民众和医疗保健专业人员对自体免疫疾病的认识程度较高，可以及时进行干预，并增加了对诊断和治疗解决方案的需求。此外，製药公司和学术机构对研发的大量投资正在促使生物製剂和先进抗甲状腺药物等创新疗法的推出，进一步提振市场。此外，政府的支持措施和有利的报销政策正在增加患者获得尖端治疗的机会，并推动北美市场的成长。

目录

第一章市场介绍

• 市场定义
• 主要目标
• 利害关係人
• 限制

第二章研究方法或前提

• 调查过程
• 调查方法
• 受访者简介

第 3 章执行摘要

• 行业概况
• 依细分市场进行预测
  • 市场成长的力量
• 区域展望

第 4 章市场动态

• 促进因素
• 机会
• 抑制因素
• 趋势
• PESTEL 分析
• 需求方分析
• 供给面分析
  • 併购
  • 投资场景
  • 产业洞察：主要新创公司及其独特策略

第五章价格分析

• 区域价格分析
• 影响价格的因素

第 6 章2022-2032 年全球格雷夫兹病市场收入

第 7 章市场分析：依治疗类型

• 抗甲状腺药物
• β受体阻断剂
• 放射性碘治疗
• 手术（甲状腺切除术）
• 辅助治疗
• 新兴疗法

第 8 章市场分析：依最终使用者划分

• 医院
• 专科诊所
• 门诊手术中心
• 家庭治疗

第 9 章市场考量：依地区

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他领域

第10章价值链分析

• 边际分析
• 进入市场的公司名单

第十一章竞争态势

• 竞争对手仪表板
• 竞争市场定位分析
• 波特五力分析

第十二章公司简介

• Merck & Co., Inc.
  • 公司概况
  • 主要财务数据
  • SWOT分析
  • 产品组合
  • 近期动态
• Abbott
• Pfizer Inc.
• GSK plc.
• AbbVie Inc.
• RLC Labs
• Mylan N.V.
• F. Hoffmann-La Roche Ltd
• Medtronic
• Ascendis Pharma

第 13 章缩写与先决条件

第14章附录

The Graves' disease market encompasses the diagnosis, treatment, and management of Graves' disease, an autoimmune disorder that leads to hyperthyroidism. Characterized by symptoms such as anxiety, rapid heartbeat, weight loss, and goiter, Graves' disease requires effective management to prevent serious complications. The market is driven by several growth factors, including the increasing prevalence of autoimmune disorders, advancements in diagnostic technologies, and the development of more effective treatment options, such as anti-thyroid medications, radioactive iodine therapy, and thyroid surgery. Additionally, rising awareness about thyroid disorders, an aging global population, and improved healthcare infrastructure further contribute to the expansion of the graves' disease market.

The market for graves disease is set to exhibit a growth rate of about 5%. This is mainly due to the technological advancements in diagnostic tools and techniques that are aiding in the early detection of graves' disease and rising investment in biopharmaceutical companies. For instance, in June 2022, Sling Therapeutics, Inc., a biopharmaceutical company launched a USD 35 million Series A financing led by TPG's The Rise Fund. The funds will support a Phase 2b clinical trial evaluating the company's investigational drug, linsitinib, for the treatment of thyroid eye disease (TED). TED predominantly affects women, and most frequently affects people with hyperthyroidism due to Graves' disease.

Based on the treatment type, the market is divided into anti-thyroid medications, beta-blockers, radioactive iodine therapy, surgery (thyroidectomy), adjunctive therapies, and emerging treatments. Among them, the anti-thyroid medications category is expected to grow at a significant rate during the forecast period by offering a non-invasive and effective treatment option for managing hyperthyroidism, a key symptom of Graves' disease. These medications work by inhibiting the production of thyroid hormones, helping to restore hormone levels to normal and alleviate symptoms. Additionally, ongoing research and development efforts to improve the efficacy and safety of these medications contribute to the growth of this segment, further driving the graves disease market.

Based on the end-user, the market is segmented into hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Homecare Settings. Among these, hospitals are significantly driving the growth of the graves disease market by serving as the primary point of care for diagnosis, treatment, and management. Hospitals provide access to specialized endocrinologists, advanced diagnostic tests, and treatments like thyroid surgery and radioactive iodine therapy. They also facilitate patient education and support programs, improving disease awareness and management. Hospitals' infrastructure and resources enable efficient care delivery, making them crucial for effective Graves' disease management worldwide.

For a better understanding of the market adoption of graves disease, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America accounts for the major share during the forecast period. The region's advanced healthcare infrastructure facilitates early diagnosis and effective management of Graves' disease, contributing significantly to market expansion. High awareness levels among the population and healthcare professionals about autoimmune disorders ensure timely intervention, thereby increasing the demand for diagnostic and therapeutic solutions. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are leading to the introduction of innovative treatments, such as biologics and advanced anti-thyroid medications, further propelling the market. Moreover, supportive government initiatives and favorable reimbursement policies enhance patient access to cutting-edge treatments, fostering market growth in North America.

Some of the major players operating in the market include Merck & Co., Inc.; Abbott; Pfizer Inc.; GSK plc.; AbbVie Inc.; RLC Labs; Mylan N.V.; F. Hoffmann-La Roche Ltd; Medtronic; Ascendis Pharma.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Graves Disease Market
• 2.2. Research Methodology of the Global Graves Disease Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL GRAVES DISEASE MARKET REVENUE (USD MN), 2022-2032F

7.MARKET INSIGHTS BY TREATMENT TYPE

• 7.1. Anti-Thyroid Medications
• 7.2. Beta-Blockers
• 7.3. Radioactive Iodine Therapy
• 7.4. Surgery (Thyroidectomy)
• 7.5. Adjunctive Therapies
• 7.6. Emerging Treatments

8.MARKET INSIGHTS BY END-USER

• 8.1. Hospitals
• 8.2. Specialty Clinics
• 8.3. Ambulatory Surgical Centers
• 8.4. Homecare Settings

9.MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10.VALUE CHAIN ANALYSIS

• 10.1. Marginal Analysis
• 10.2. List of Market Participants

11.COMPETITIVE LANDSCAPE

• 11.1. Competition Dashboard
• 11.2. Competitor Market Positioning Analysis
• 11.3. Porter Five Forces Analysis

12.COMPANY PROFILED

• 12.1. Merck & Co., Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Key Financials
  • 12.1.3. SWOT Analysis
  • 12.1.4. Product Portfolio
  • 12.1.5. Recent Developments
• 12.2. Abbott
• 12.3. Pfizer Inc.
• 12.4. GSK plc.
• 12.5. AbbVie Inc.
• 12.6. RLC Labs
• 12.7. Mylan N.V.
• 12.8. F. Hoffmann-La Roche Ltd
• 12.9. Medtronic
• 12.10. Ascendis Pharma

13.ACRONYMS & ASSUMPTION

14.ANNEXURE